Mehdi H. Hamadani, MD

Professor

view physician profile

Locations

Froedtert Hospital
Clinical Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Clinical Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is A a professor of medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.

(Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, Baird J, Bezerra E, Farooq U, Fung H, Khurana A, Lekakis L, Lutfi F, McCarty J, Mukherjee A, Nath R, Romancik J, Schuster SJ, Smith M, Winter A, Turtle C, Sauter C, Shadman M, Herrara A, Hamadani M.) Am J Hematol. 2025 Jul;100(7):1152-1162 PMID: 40231369 SCOPUS ID: 2-s2.0-105002610922 04/15/2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.

(Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M.) Blood. 2025 Jun 05;145(23):2762-2767 PMID: 39938007 02/12/2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.

(Dreger P, Ahmed S, Bazarbachi A, Dietrich S, Fenske TS, Ghosh N, Hermine O, Hamadani M.) Bone Marrow Transplant. 2025 Jun;60(6):759-768 PMID: 40229536 PMCID: PMC12151868 04/15/2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.

(Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS.) J Clin Oncol. 2025 May 10;43(14):1695-1705 PMID: 39946666 PMCID: PMC12058369 02/13/2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

(Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC.) Bone Marrow Transplant. 2025 May;60(5):632-639 PMID: 40025178 03/03/2025
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.

(Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G.) Bone Marrow Transplant. 2025 May;60(5):746 PMID: 40016514 SCOPUS ID: 2-s2.0-85219054353 02/28/2025
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.

(Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS.) Transplant Cell Ther. 2025 May;31(5):285-296 PMID: 39961473 02/18/2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

(Goyal A, O'Leary D, Dabaja B, Weng WK, Zain J, Cutler C, Guitart J, Kim YH, Geskin LJ, Hoppe RT, Wilson LD, Beaven AW, Horwitz S, Allen PB, Barta SK, Bohjanen K, Brammer JE, Carter JB, Comfere N, DeSimone JA, Dusenbery K, Duvic M, Huen A, Jagadeesh D, Kelsey CR, Khodadoust MS, Lechowicz MJ, Mehta-Shah N, Moskowitz AJ, Olsen EA, Poh C, Pro B, Querfeld C, Sauter C, Sokol L, Sokumbi O, Wilcox RA, Zic JA, Gru A, Hamadani M, Foss F.) J Am Acad Dermatol. 2025 Apr 06 PMID: 40199382 04/09/2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

(Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, Gauger K, Desai AG, Chen MM, Li KL, Rotibi M, Syed U, Vusirikala M, Harrington A, Atallah EL.) Leukemia. 2025 Apr;39(4):837-843 PMID: 39955432 SCOPUS ID: 2-s2.0-85218187693 02/16/2025
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.

(Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS.) J Clin Oncol. 2025 Mar 31:JCO2402158 PMID: 40163793 03/31/2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

(Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N.) Blood Cancer J. 2025 Mar 26;15(1):45 PMID: 40140364 PMCID: PMC11947194 03/27/2025
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

(Siegel SJ, DeWolf S, Schmalz J, Saber W, Dong J, Martens MJ, Logan B, Albanese A, Iovino L, Chen E, Kaminski J, Neuberg D, Hebert K, Keskula P, Zavistaski J, Steinberg L, Schichter I, Cagnin L, Hernandez V, Warren M, Applegate K, Bar M, Chhabra S, Choi SW, Clark W, Das S, Jenq R, Jones RJ, Levine JE, Murthy H, Rashidi A, Riches M, Sandhu K, Sung AD, Larkin K, Al Malki MM, Gooptu M, Elmariah H, Alousi A, Runaas L, Shaffer B, Rezvani A, El Jurdi N, Loren AW, Scheffey D, Sanders C, Hamadani M, Dudakov J, Bien S, Robins H, Horowitz M, Bolaños-Meade J, Holtan S, Bhatt AS, Perales MA, Kean LS.) medRxiv. 2025 Feb 26 PMID: 40061351 PMCID: PMC11888538 03/10/2025